In a publication in Science, Noam Zelcer from the Division of Biopharmaceutics describes a previously unrecognized pathway to regulate LDL-cholesterol levels. He is also able to modulate this pathway. This opens the possibility for complementing and improving the efficacy of statins: A class of drugs used to remove ‘bad cholesterol’ from the bloodstream.